Ventyx Biosciences, Inc. (VTYX)

2.5100 0.0000 (0.00%) 收市：04:00PM EDT

Ventyx Biosciences, Inc.

12790 El Camino Real
Suite 200
San Diego, CA 92130
United States
760 593 4832
https://ventyxbio.com

版塊: Healthcare
行業: Biotechnology
全職員工: 74

描述

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

公司管治

截至 2024年6月1日 止，Ventyx Biosciences, Inc. 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中：2；董事會：9；股東權利：8；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。